戴纳基公司近日宣布，其针对杜氏肌营养不良症（DMD）研发的Z-Rostudirsen药物在DELIVER临床试验中取得了新的积极心肺功能数据。这项突破性进展标志着该疗法在改善患者心肺系统关键指标方面展现出显著潜力，为DMD治疗领域注入了新的希望。
试验结果显示，Z-Rostudirsen在多项心肺功能评估参数上均表现出具有临床意义的改善。这些数据进一步验证了该药物通过靶向治疗机制对DMD患者心血管和呼吸系统产生的积极影响。研究人员指出，这一成果为后续临床开发奠定了坚实基础。
目前，戴纳基正在深入分析这些最新数据，并计划与监管机构讨论下一步临床开发策略。该公司表示将持续推进Z-Rostudirsen的研发进程，力争为DMD患者提供更有效的治疗方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.